Long‐Term Outcomes of Sofosbuvir/Velpatasvir Treatment for Hepatitis C Virus‐Related Decompensated Cirrhosis: A Retrospective Multicenter Cohort Study

20260 citationsJournal Article

Authors

Satoru Kakizaki · National Hospital Organization Takasaki Medical Center

Tadashi Ikegami · Tokyo Medical University Ibaraki Medical Center

Takeshi Hatanaka · Gunma Saiseikai Maebashi Hospital

Y. Suzuki · National Hospital Organization Takasaki Medical Center

Takashi Hoshino · National Hospital Organization Takasaki Medical Center

Atsushi Naganuma · National Hospital Organization Takasaki Medical Center

Abstract

SOF/VEL therapy achieved high SVR rates and demonstrated that post-treatment improvement in the ALBI score is strongly associated with a favorable long-term prognosis in patients with decompensated cirrhosis.

Topics & Keywords

Hepatitis C virus research Liver Disease and Transplantation Drug-Induced Hepatotoxicity and Protection

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Hepatology Research

DOI: 10.1111/hepr.70172

Field-Weighted Citation Impact: 0.00

Command Palette